Bacterial mediated thf alpha gene silencing

US2015017138A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2015017138-A1
Application numberUS-201414328900-A
CountryUS
Kind codeA1
Filing dateJul 11, 2014
Priority dateJun 15, 2007
Publication dateJan 15, 2015
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.

First claim

Opening claim text (preview).

What is claimed is: 1 . A method of delivering one or more siRNAs to mammalian cells, the method comprising introducing to said mammalian cells at least one invasive bacterium containing one or more siRNAs or one or more DNA molecules encoding one or more siRNAs, wherein the expressed siRNAs interfere with the mRNA of TNFα. 2 . An invasive bacterium comprising one or more siRNAs or one or more DNA molecules encoding one or more siRNAs, wherein the expressed siRNAs interfere with the mRNA of TNFα. 3 . A prokaryotic vector comprising at least one DNA molecule encoding one or more siRNAs and at least one RNA-polymerase III compatible promoter or at least one prokaryotic promoter, wherein the expressed siRNAs interfere with the mRNA of TNFα. 4 . The method of claim 1 , wherein said invasive bacterium is a non-pathogenic or non-virulent bacterium. 5 . The method of claim 1 , wherein said invasive bacterium is a therapeutic bacterium. 6 . The method of claim 1 , wherein said mammalian cell is in vivo or in vitro. 7 . The method of claim 1 , wherein said mammalian cell is selected from the group consisting of human, bovine, ovine, porcine, feline, buffalo, canine, goat, equine, donkey, deer, avian, bird, chicken and primate cells. 8 . The method of claim 1 , wherein the mammalian cell is selected from the group consisting of a gastrointestinal epithelial cell and a macrophage. 9 . The method of claim 1 , wherein said one or more DNA molecules encoding said one or more siRNAs are transcribed within the animal cell. 10 . The method of claim 1 , wherein said one or more DNA molecules encoding said one or more siRNAs are transcribed within the bacterium. 11 . The method of claim 1 , wherein said one or more DNA molecules encoding one or more siRNAs comprise a prokaryotic promoter. 12 . The method of claim 11 , wherein said prokaryotic promoter is a T7 promoter. 13 . The method of claim 1 , wherein said animal cells are infected with about 10 3 to 10 11 viable invasive bacteria. 14 . The method of claim 1 , wherein said animal cells are infected at a multiplicity of infection ranging from about 0.1 to 10 6 . 15 . The method of claim 1 , wherein the expressed siRNAs direct the multienzyme complex RNA-induced silencing complex of the cell to interact with the mRNA of TNFα. 16 . The method of claim 1 , wherein expression of TNFα is decreased or inhibited, 17 . The invasive bacterium of claim 2 , wherein said invasive bacterium is a non-pathogenic or non virulent bacterium. 18 . The invasive bacterium of claim 2 , wherein said invasive bacterium is a therapeutic bacterium. 19 . A composition comprising the bacterium of claim 2 and a pharmaceutically acceptable carrier. 20 . A eukaryotic host cell comprising the bacterium of claim 2 , and a pharmaceutically acceptable carrier.

Assignees

Inventors

Classifications

  • C12N15/63Primary

    Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

  • General methods applicable to biologically active non-coding nucleic acids · CPC title

  • spanning the whole gene, or a large part of it · CPC title

  • against growth factors, growth regulators, cytokines, lymphokines or hormones · CPC title

  • against viruses · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2015017138A1 cover?
Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one o…
Who is the assignee on this patent?
Beth Israel Hospital
What technology area does this patent fall under?
Primary CPC classification C12N15/63. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Jan 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).